Fri, Jul 25, 2014, 8:36 AM EDT - U.S. Markets open in 54 mins.


% | $
Click the to save as a favorite.

Exelixis, Inc. Message Board

xwavve 30 posts  |  Last Activity: Jul 23, 2014 7:49 AM Member since: Aug 16, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • STEM was upgraded today at Chardan Capital, and the firm issued a price target of $4.0. They have also indicated that STEM will release their AMD data on June 19 prior to the market opening. Depending on how large the efficacy signal is, this has the potential to be transformative for the company.

  • xwavve by xwavve Jun 10, 2014 10:06 AM Flag

    1) Fiorino introduced - will make the rounds with US bankers
    2) Israeli press profiles a 2nd super responder - a soldier. Company considering translating for US news outlets
    3) Slides will not be distributed for 2a results due to pending publication of data by PI. Waiting for final 2 patients to complete follow-up in August
    4) Company preclinical models of NurOwn in AZ show consistent effects across the board -- nice pipeline expansion for attracting funding
    5) Tech transfer completed at 2 additional manufacturing sites - looking to consolidate an approach
    6) Publication of 2a results could qualify for FDA breakthrough status - publication to be in major journal
    7) Trials moving forward and company believes their technology is better than competitors - working on improvements to share price
    8) No discussion of up-listing or reverse stock split
    9) No negative news (other than visibility issues being in Israel) - Fiorino thrown in the fire, but performed well

  • Patient data will be released mid June for the P1/2 AMD trial. Interim data for the first cohort will be presented, those receiving a transplant of 200k cells each. The second cohort will complete by the end of June for the high dose, 1M cells.

    Odds appear good that a positive efficacy signal will be seen at the low dose. The company is heavily communicating in advance of the release, and has announced plans for a P2. This would be a transformative event for the company, as stem cell trial results have been underwhelming based on the original prospects once held for field.

    The market for AMD is large, and this would be a tremendous commercial success if the results continue to demonstrate efficacy. Bottom-line: Decent odds for an efficacy signal.

  • CFO noted on CC that VA/Military channel is not reporting in IMS RX and represents a very large percentage of the pie. Additionally, Europe is also not in this estimate. Revenue estimates based on scripts fall quite short of actuals. 2nd quarter likely $3.4 to $4.0 billion. The CFO comments have sparked the rally.

  • MRI is still missing - after all those blogs and press discussion by the CEO. The only direct measurement of depression was not significant in the trial - MADRS - yet the headlines screamed success. Even the consultant (that's how he was originally described?), FAVA, was promoted to a co-PI. A promotion, as I'm sure he's glad to help if CUR signs a contract for the phase 2 remote raters facilitated by Mass Gen? Now, that's good psychology.

  • In this case, CUR is unlikely to have a viable product following BCLI current success in 2a, and likely future success.

    NSI 189 does not have any definitive data demonstrating its efficacy, and the company has mischaracterized the results, IMHO. Garr, once again, guided for MRI results for a year and the held them, and, after a year of calling Fava a consultant, promoted him to co-PI. All slippery PR moves to raise share price, IMHO. It worked, for awhile, and now the company will likely experience a large pull back, IMHO.

    The share price, following the dilution, will provide for the company to continue operations for another decade of losses, if ALS is shelved. Or, more succinctly, salaries for staff. As the company became more well known, Garr's manipulation of the press, IMHO, is more widely known. He will now have to dilute prior to BCLI releasing full results for their 2a program. BCLI is also likely to have a compassionate use program putting further pressure on CUR to the downside. BCLI has the limelight.

    Anticipate, dilution and further share price erosion.

  • The spin factor:
    1) NSI 189 MRI data promoted for a year and now unavailable
    2) NSI 189 shows no statistically significant efficacy on only direct depression scale used in the study - MADRS. Company misleads by promoting the effect size which is not significant
    3) NSI cognitive scale results have an unmatched baseline between placebo an active making a comparison invalid IMHO
    4) Company promoted Mexican ALS site
    5) Majority of patients in P1 trial did not benefit from treatment - Dr. Feldman claims it is too early to tell if treatment is effective yet company promotes otherwise.
    6) CUR promotes anecdotal patient blogs for patients claiming positive results, but other patients claim to be worse off -- benefit is not verified yet.
    7) CUR promotes right to try in Colorado, but will never treat a patient there. Stunt will backfire severely with the FDA
    8) BCLI treatment has a statistically significant result in their 2a interim and full results are do shortly. The therapy does not require surgery or immunosuppression.
    9) Large shelf registration was a large miscalculation.
    10) STEM is the likely owner of the relevant patents, and has pursued a much more commercially viable clinical pathway with AMD.
    11) Repeating STEMS's program in SCI is a waste of funds - success in this area has been fleeting

    Conclusions: CUR is likely to be surpassed by BCLI an any effect appears to be neurotrophic rather than related to engraftment. NSI 189 data are inconclusive - no evidence it works. Company also has conspicuously back-tracked on MRI data. Management, time and again, misguides investors and unethically promotes trial results without fair balance IMHO. BCLI is now the company to watch in ALS. SELL.

  • Now two Brainstorm sites enrolling patients -- and there has been a frenzy of applicants. No surgery and no immunosuppression. Stat sig 2a data.

    Garr is still focused on opening his Mexican ALS site, right to try in Colorado etc - things that will not ever happen. PR stunts?

    CUR surgery is too invasive and Brainstorm appears to have better results with a therapy that can be administered chronically. And, now they are trying to repeat STEM's work in SCI with the analogous cells. SCI has been an extremely slow clinical investigation, driving one company broke, and not likely to yield any commercial results a decade, if at all.

    STEM likely to win with AMD if ACTC doesn't leapfrog them...

    You see full 2a Brainstorm data before year-end, and that is likely extremely difficult news for CUR. Not a bright move with $150 million shelf. What a shame.

  • No oral presentation involved. Typical Neuralstem spin. According to the abstract for June 24 it does not include MRI data, and Garr, despite all his missed guidance on revealing the data, has not indicated that data will include MRI results. Perhaps it will be presented on the 17th - but again - the company does not confirm... Garr misleads - I would wait for actual results before speculating. MRI doesn't appear likely. Original guidance listed Fava as only a consultant, who post study became a co-PI. Is that ethical?

  • StemCells will release interim AMD data June 18. This is an area where stem cells could prove a large commercial success in a short period of time. Based on existing early data with stem cells, there would appear to be a very good chance the company will have observed an efficacy signal. Mark you calendars.

  • Reply to


    by judijudi44 Jun 1, 2014 6:11 PM
    xwavve xwavve Jun 1, 2014 6:25 PM Flag

    There should be a press release in the am. Interestingly, Capricor partnered very early with JNJ on their stem cell derivative for repairing MI damage. This may be the case here as the company indicated on their conference call that they had significant company interesest and signed confidentiality agreements (providing data review). Capricor received $12.5 million upfront for JNJ and $375 in milestones + royalties. They are also a penny stock.

  • Sensory gains appear permanent and progressive. These type of changes have never been seen in these types of injuries. Surgery holds tremendous promise. Higher doses of cells may be even more effective.

  • xwavve by xwavve Jun 9, 2014 6:46 PM Flag

    1) No MRI data June 24 - Just a qEEG poster (see actual congress program)
    2) 566 eclipsed by BCLI NUROWN with P2a data and potential BT status
    3) Garr challenges the FDA - even though he has yet to publish positive efficacy data from any P2 trial

  • Sovaldi sales should just exceed $4 billion, and if these two decisions are positive, look for $120 and a stock split after holding above $100 for 60 days.

  • Lebovits indicated on the April 28 conference call that they have been contacted by major pharmaceutical companies, signed confidentiality agreements, and had these companies review their data. He was quite confident that they would be able to raise money, and clearly articulated this may non-dilutive from a partnership, or other type of direct investment.

    Lebovits also indicated they felt their approach was superior to Neuralstem (but didn't want to speak badly of another company in the ALS field), but that it was far too invasive. It is clear they have results which are consistently positive, but only last for months -- and this is variable from patient to patient.

    Their results look superior to Neuralstem, in the few patients they revealed, but this may become more clear June 1, tomorrow, from the release of 2a data.

    Visibility is their main issue, and from the clunks asking questions on the CC, this is clear. They hope to hire a US CEO to improve curb appeal.

    Bottom-line: BCLI is was extremely confident in their data, and clear that companies were approaching them, signing confidentiality agreements, and reviewing their data. Neuralstem market cap is nearly 10x BCLI, yet BCLI, will quickly move ahead of CUR because patients can be dosed all at once - in fact in several weeks if they are pre-identified. They then stay in the hospital 1-2 days, but this is only mandated by protocol. Looking forward to data release tomorrow.

  • The path forward has a good probability playing out as follows:

    1) In Vivo results confirmed in American Journal of Ophthalmology - vision improvement in over 50 percent of patients with spectacular results in some. This would appear to be superior to STEM's results, where further vision loss was only prevented in AMD patients. However, there may be room for both these cells..
    2) With no current treatment for dry AMD, the market cap should approach $750 million to $1 billion, with a headline that some blind patients can now see. Share price should rise to a corresponding 22 to 39 cents. Approximately 3 to 4x current price. The largest investor opportunity for the next 6 months appears to be in the coming weeks, when the data will be presumably published, and positive.
    3) ACTC is approved for either a 30 to 1, or 100 to 1 reverse stock split. I expect that once the data are published, assuming they are positive, the company with reverse 30 to 1. This will bring the share price to the $5 to $6 range, and facilitate the uplisting to NASDAQ. A reasonable assumption is that this will occur in Q.1.15.
    4) A definitive phase 2/3 study will be put in place, an the company will receive breakthrough status in December.
    5) Stock price may trade $7-9, split adjusted, on this path of milestones.

  • Company has already indicated that over 50 percent of the patients improved, or had spectacular results in P1/2. Schwartz was on the agenda at the recent ISSCR conference several weeks ago, but did not present his session. This appears to indicate that the company had anticipated the results would have been available by the time of the conference.

    It is reasonably probable that the share price will exceed .24 - $30 billion in world-wide potential with no effective treatment for improving dry AMD. 3x bagger on approval.

  • Reply to

    New Shares Authorized: 150000

    by xwavve Jul 8, 2014 6:51 PM
    xwavve xwavve Jul 8, 2014 6:56 PM Flag

    Current shares outstanding 87 mil. Now add 150 million shares. LOL. Maybe the MRI data are positive - large effect size positive :)

  • Here is a copy of the results section from today's presentation. The company has not yet PR released actual results. Unfortunately, Marty was confused regarding the date of the presentation. Hopefully, it will be released shortly. A bit of an embarrassment - not knowing when your own data will be presented - not like there is a lot of it ;). The following is the results and conclusions section from the ASIA published abstract.

    Results: A total of 12 subjects, between 3-12 months (AIS A) and 3-24 months (AIS B and C)
    post-injury will undergo transplantation with HuCNS-SC. The interim follow-up safety data for
    the AIS A and AIS B subjects to date will be presented, along with representative segmental
    clinical and neurophysiological assessments.

    Conclusion: The presentation will focus on the value of segmental testing in subjects with
    thoracic spinal cord injury and the inclusion of incomplete SCI subjects to improve the
    sensitivity of safety and preliminary efficacy assessments following HuCNS-SC intramedullary

  • It just occurred to me last night --- wouldn't it make perfect sense for TEVA to partner with BCLI? They are marketers of Copaxone -- exactly the direction BCLI is going with NUROWN following ALS.

4.21-0.06(-1.43%)Jul 24 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Puma Biotechnology, Inc.
NYSEThu, Jul 24, 2014 4:02 PM EDT
Xerox Corporation
NYSEThu, Jul 24, 2014 4:01 PM EDT